Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› NSCLC
Clinical trial register · United States · industry-sponsored

NSCLC Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9183 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 02 Nov 2026, 03:16 UTC
9183
Studies in scope
industry-sponsored, all four open statuses
4981
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
California 22 Florida 15 New York 13 Illinois 10 Massachusetts 9
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

NSCLC trials in the USA

31 of 9183 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Gilead Sciences
Phase 2
80
California, New Jersey
2026-11
Recruiting
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
NCT07887971NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
Aktis Oncology, Inc.
Phase 1
152
Florida
2026-11
Recruiting
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
NCT07873450Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
Full-Life Technologies UK Limited
Phase 1/2
208
Minnesota
2026-10-01
Recruiting
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
NCT07784959ALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC, ALK+ Non-Small-Cell Lung Carcinoma
Nuvectis Pharma, Inc.
Phase 1
54
Virginia
2026-08-17
Recruiting
Revolution Medicines, Inc.
Phase 3
430
Florida
2026-08-14
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
Revolution Medicines, Inc.
Phase 1/2
370
California, Connecticut, Minnesota, Tennessee, Texas, Virginia
2026-01-30
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
183
Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts
2025-05-31
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
Revolution Medicines, Inc.
Phase 3
590
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-05-06
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Recruiting
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
NCT06816992Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
ORIC Pharmaceuticals
Phase 1
76
New York, Virginia
2025-02-27
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Recruiting
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Active, closed
Eikon Therapeutics
Phase 2
70
Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois
2024-02-06
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
California, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia
2023-09-26
Recruiting
CJ Bioscience, Inc.
Phase 1/2
160
California, Pennsylvania
2023-09-11
Active, closed
AstraZeneca
Phase 3
1,350
Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Iowa
2022-12-29
Recruiting
Orano Med Theranostics, SAS
Phase 1
48
Illinois, Iowa, Kentucky, Maryland, Nebraska, Pennsylvania
2022-12-22
Active, closed
Genentech, Inc.
Phase 1
165
California, Colorado, Florida, Georgia, Massachusetts, Missouri, New Jersey, Tennessee
2022-10-20
Active, closed
Study of Oral MRT-2359 in Selected Cancer Patients
NCT05546268NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
Monte Rosa Therapeutics, Inc
Phase 1/2
174
Arizona, California, Connecticut, Kansas, Massachusetts, Michigan, Missouri, New York
2022-10-12
Recruiting
Ellipses Pharma
Phase 1/2
265
California, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan, New York
2022-09-30
Recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Indiana, Texas, Washington
2022-08-25
Active, closed
BioAtla, Inc.
Phase 1/2
320
California, Georgia, Indiana, New Jersey, New York, Ohio, Oregon, Utah
2022-08-03
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
California
2021-12-28
Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
TORL Biotherapeutics, LLC
Phase 1
90
California, Kentucky, Minnesota, New York, Ohio, Texas, Virginia
2021-11-17
Active, closed
Cullinan Therapeutics Inc.
Phase 1
440
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, New York, North Carolina
2021-10-29
Active, closed
Pfizer
Phase 3
77
Arkansas, California, Florida, New Jersey, New York, Pennsylvania, Texas, Washington
2021-09-29
Recruiting
Vivace Therapeutics, Inc
Phase 1/2
434
California, Illinois, Massachusetts, Minnesota, New York, Texas, Virginia
2021-03-24
Active, closed
Study to Evaluate D-1553 in Subjects With Solid Tumors
NCT04585035Solid Tumor, Adult, NSCLC, CRC
DrugD-1553
InventisBio Co., Ltd
Phase 1/2
180
California, Kentucky, Michigan, New York, Oregon
2020-10-02
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
95
California, District of Columbia, Florida, Massachusetts, New York, Pennsylvania, Texas
2020-01-07
Rows per page Showing 1–31 of 31
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/nsclc

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,183 studies in total at the last sync on 02 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 31 of those studies listing the condition NSCLC.

How many NSCLC trials are recruiting in the US?

20 of the 31 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (NSCLC), 31 studies
PhaseStudiesRecruitingShare
Phase 1/2141045.2%
Phase 19729%
Phase 35316.1%
Phase 2206.5%
Phase 4103.2%

Most active sponsors

Lead sponsors with the most studies (NSCLC)
Lead sponsorStudiesRecruiting
Revolution Medicines, Inc.33
Gilead Sciences21
Pfizer20
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)22
A2 Biotherapeutics Inc.11
Aktis Oncology, Inc.11
AstraZeneca10
BioAtla, Inc.10
CJ Bioscience, Inc.11
Cullinan Therapeutics Inc.10

Top states

Top states (NSCLC), by number of studies with a site there
StateStudies
California22
Florida15
New York13
Illinois10
Massachusetts9
Texas9
Colorado6
Connecticut6
Michigan6
Minnesota6
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.